Day 3 (2021)
Over the past 50 years, our mission at the National Headache Foundation has been to further awareness of headache and migraine as legitimate neurobiological diseases. Much has changed during this time. With aid from advanced technology and clinical innovation, there are more treatment options than ever before. However, we understand that these diseases are still largely misunderstood and that finding the right treatment options for you requires insight.
Impel NeuroPharma, Inc. is a late-stage biopharmaceutical company focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. Impel NeuroPharma is the first company to investigate targeting the upper nasal space with optimized therapeutic molecules and formulations for treating CNS diseases.
Jan Lewis Brandes, MD
Assistant Clinical Professor of Neurology
Dale Bond, PhD
Professor of Psychiatry & Human Behavior (Research)
The Miriam Hospital and Brown Alpert Medical School Weight Control and Diabetes Research Center
Deborah Friedman, MD, MPH, FAAN
Professor of Neurology & Ophthalmology
Jan Hoffmann, MD, PhD
Clinical Senior Lecturer & Honorary Consultant in Neurology
King's College London
Nada Hindiyeh, MD
Clinical Assistant Professor & Director of Clinical Research in Headache Medicine